Non-randomized, open, two-cohort, phase II, multicenter national clinical trial. 20 sites in
Cohort 1 includes soft-tissue sarcoma and osteosarcoma (21 patients), while Cohort 2 includes
chordoma patients only (19 patients).
Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive
days followed by 7 rest days to comprise a complete cycle of 28 days. Treatment will continue
until disease progression, development of unacceptable toxicity, non-compliance, withdrawal
of consent by the patient or investigator decision.
The main goal is to determine progression-free survival rate (PFSR) according to RECIST 1.1
at 6 months.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.